Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Habitual coffee consumption and blood pressure: An epidemiological perspective

Authors Johanna M Geleijnse

Published 10 October 2008 Volume 2008:4(5) Pages 963—970


Review by Single-blind

Peer reviewer comments 3

Johanna M Geleijnse

Division of Human Nutrition, Wageningen University, The Netherlands

Abstract: This paper summarizes the current epidemiological evidence on coffee consumption in relation to blood pressure (BP) and risk of hypertension. Data from crosssectional studies suggest an inverse linear or U-shaped association of habitual coffee use with BP in different populations. Prospective studies suggest a protective effect of high coffee intake (4 or more cups per day) against hypertension, mainly in women. Furthermore, the risk of hypertension may be lower in coffee abstainers. Randomized controlled trials, which are mostly of short duration (1–12 weeks), have shown that coffee intake around 5 cups per day causes a small elevation in BP (∼2/1 mmHg) when compared to abstinence or use of decaffeinated coffee. With regard to underlying biological mechanisms, most research has been devoted to BP-raising effects of caffeine. However, there are many other substances in coffee, such as polyphenols, soluble fi bre and potassium, which could exert a beneficial effect in the cardiovascular system. Although the precise nature of the relation between coffee and BP is still unclear, most evidence suggests that regular intake of caffeinated coffee does not increase the risk of hypertension.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Engineered collagen hydrogels for the sustained release of biomolecules and imaging agents: promoting the growth of human gingival cells

Choi J, Park H, Kim T, Jeong Y, Oh MH, Hyeon T, Gilad AA, Lee KH

International Journal of Nanomedicine 2014, 9:5189-5201

Published Date: 11 November 2014

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients

Shigematsu T, Nakashima Y, Ohya M, Tatsuta K, Koreeda D, Yoshimoto W, Yamanaka S, Sakaguchi T, Hanba Y, Mima T, Negi S

International Journal of Nephrology and Renovascular Disease 2012, 5:81-89

Published Date: 29 May 2012

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery

Turan-Vural E, Torun-Acar BT, Kivanc SA, Acar S

Clinical Ophthalmology 2011, 5:881-885

Published Date: 29 June 2011

Novel formulation and evaluation of a Q10-loaded solid lipid nanoparticle cream: in vitro and in vivo studies

Farboud ES, Nasrollahi SA, Tabbakhi Z

International Journal of Nanomedicine 2011, 6:611-617

Published Date: 30 March 2011

The role of insulin detemir in overweight type 2 diabetes management

Yared N Demssie, Naveed Younis, Handrean Soran

Vascular Health and Risk Management 2009, 5:553-560

Published Date: 29 June 2009

Epidemiologic characteristics and risk factors for renal cell cancer

Loren Lipworth, Robert E Tarone, Lars Lund, Joseph K McLaughlin

Clinical Epidemiology 2009, 1:33-43

Published Date: 3 April 2009

Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes

Sandra Beer, François Feihl, Juan Ruiz, Irène Juhan-Vague, Marie-Françoise Aillaud, et al

Vascular Health and Risk Management 2008, 4:1449-1458

Published Date: 5 December 2008

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin

Anbu Pandian, Anjali Arora, Laurence S Sperling, Bobby V Khan

Vascular Health and Risk Management 2008, 4:1001-1009

Published Date: 10 October 2008